Scientific Opinion on Rovabio® Excel (endo-1,3(4)-beta-glucanase and endo-1,4-beta-xylanase) as a feed additive for chickens and turkeys for fattening, laying hens, piglets (weaned) and pigs for fattening, ducks, guinea fowls, quails, geese, pheasants and pigeons by EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
   EFSA Journal 2013;11(7):3321 
 
Suggested citation: EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 
2013. Scientific opinion on Rovabio
® Excel (endo-1,3(4)-beta-glucanase and endo-1,4-beta-xylanase) as a feed additive for 
chickens and turkeys for fattening, laying hens, piglets (weaned) and pigs for fattening, ducks, guinea fowls, quails, geese, 
pheasants and pigeons. EFSA Journal 2013;11(7):3321, 26 pp. doi:10.2903/j.efsa.2013.3321 
Available online: www.efsa.europa.eu/efsajournal  
© European Food Safety Authority, 2013 
 SCIENTIFIC OPINION 
Scientific Opinion on Rovabio
® Excel (endo-1,3(4)-beta-glucanase and 
endo-1,4-beta-xylanase) as a feed additive for chickens and turkeys for 
fattening, laying hens, piglets (weaned) and pigs for fattening, ducks, guinea 
fowls, quails, geese, pheasants and pigeons
1 
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Rovabio
® Excel is an enzyme preparation (solid and liquid forms) of endo-1,3(4)-beta-glucanase and endo-1,4-
beta-xylanase, produced by a non-genetically modified strain of Penicillium funiculosum (Talaromyces versatilis 
sp. nov.). The additive is to be used as a feed additive for chickens and turkeys for fattening, laying hens, piglets 
(weaned) and pigs for fattening, ducks, guinea fowls, quails, geese, pheasants and pigeons.  Tolerance trials 
performed in chickens and turkeys for fattening, laying hens and piglets showed that the animals tolerated well 
200-fold  (chickens,  turkeys  and  piglets)  or  20-fold  (laying  hens)  the  recommended  dosage.  Therefore,  the 
additive is safe for these target species at the recommended dose. The conclusion can be extended to pigs for 
fattening and can be extrapolated to ducks, guinea fowls, quails, geese, pheasants and pigeons provided that the 
same dose applies. The fermentation product used for the preparation of the additive gave negative results for 
mutagenicity. The results obtained in a sub-chronic oral toxicity study raised no concerns regarding the product. 
Therefore, the additive gives rise to no concern for consumer safety. No risks to the environment are expected 
from the use of the product as a feed additive. Based on the results obtained in the efficacy trials provided in 
chickens and turkeys for fattening, laying hens, piglets (weaned) and pigs for fattening, it is concluded that the 
additive has the potential to be efficacious at the recommended dose. These conclusions can be extrapolated to 
ducks, guinea fowls, quails, geese, pheasants and pigeons. The Panel proposes a recommendation to modify the 
specifications of the additive. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Additives  and  Products  or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on Rovabio
® 
Excel (endo-1,3(4)-beta-glucanase and endo-1,4-beta-xylanase) as a feed additive for chickens and 
turkeys for fattening, laying hens, piglets (weaned) and pigs for fattening, ducks, guinea fowls, quails, 
geese, pheasants and pigeons. 
The  enzymes  are  produced  by  a  non-genetically  modified  strain  of  Penicillium  funiculosum 
(Talaromyces versatilis sp. nov.) and the additive is available in two solid and two liquid forms. A 
solid and a liquid formulation of the additive are currently authorised for use as a feed additive for 
chickens and turkeys for fattening, laying hens, ducks, weaned piglets and pigs for fattening. The 
applicant requested that the additive be re-evaluated for use in these species/categories and that its use 
in feed be extended to guinea fowls, quails, geese, pheasants and pigeons. 
The solid and the liquid formulations are considered equivalent in terms of safety and efficacy for the 
target species, provided that the same dose in enzyme units applies. 
Based on the results obtained in tolerance trials performed in chickens and turkeys for fattening, laying 
hens and piglets, in which the animals tolerated well 200-fold (chickens, turkeys and piglets) or 20-
fold (laying hens) the recommended dosage, the FEEDAP Panel concludes that the additive is safe for 
these target species at the recommended dose. The conclusion can be extended to pigs for fattening 
provided that the same dose applies. Considering the margin of safety demonstrated in major poultry 
species, the conclusions on the safety for these species can be extrapolated to ducks, guinea fowls, 
quails, geese, pheasants and pigeons. 
The  fermentation  product  used  for  the  preparation  of  the  additive  gave  negative  results  for 
mutagenicity. The results obtained in a sub-chronic oral toxicity study raised no concerns regarding 
the product. Therefore, the additive does not give rise to any concern for consumer safety. 
Two formulations (Rovabio
® Excel AP and LC2) were tested for skin and eye irritation and showed no 
evidence of causing such effects. The other two formulations (AP T-Flex and LC) were not tested but, 
based on their composition, their irritant potential is unlikely to be significantly different from that of 
their tested counterparts. In the absence of data on its skin sensitisation properties, and taking account 
of its proteinaceous nature, the additive is to be considered a potential skin and respiratory sensitiser. 
The active substances of Rovabio
® Excel are proteins, and as such will be degraded/inactivated during 
the passage through the digestive tract of animals. Therefore, no risks to the environment are expected 
and no further environmental risk assessment is required. 
Based on the results obtained in the efficacy trials provided in chickens and turkeys for fattening, 
laying hens, piglets (weaned) and pigs for fattening, the FEEDAP Panel concludes that the additive 
has the potential to be efficacious at the recommended dose. The mode of action of the enzymes 
glucanase and xylanase is well known and can be considered to be similar in all poultry species. 
Therefore, the conclusions on the efficacy in major poultry species can be extrapolated to ducks, 
guinea fowls, quails, geese, pheasants and pigeons. 
The Panel proposes a recommendation to modify the specifications of the additive. Rovabio
® Excel for poultry and pigs 
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BACKGROUND 
Regulation  (EC)  No  1831/2003
4  establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7. Article 10(2) of that Regulation also specifies that for 
existing products within the meaning of Article 10(1), an application shall be submitted in accordance 
with Article 7, at the latest one year before the expiry date of the authorisation given pursuant to 
Directive 70/524/EEC for additives with a limited authorisation period, and within a maximum of 
seven years after the entry into force of this Regulation for additives authorised without a time limit or 
pursuant to Directive 82/471/EEC. 
The European Commission received a request from the company ADISSEO
5 for the authorisation 
under article 4 and the re-evaluation under Article 10 of Regulation (EC) No 1831/2003 of the product 
Rovabio
® Excel, endo-1,3(4)-beta-glucanase and endo-1,4-beta-xylanase, when used as a feed additive 
for chickens for fattening, turkeys for fattening, laying hens, piglets (weaned), pigs for fattening, 
ducks, guinea fowls, quails, geese, pheasants, pigeons (category: zootechnical additive; functional 
group: digestibility enhancers) under the conditions mentioned in Table 1.  
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application  to  the  European  Food  Safety  Authority  (EFSA)  as  an  application  under  Article  4(1) 
(authorisation of a feed additive or new use of a feed additive) and under Article 10(2) (re-evaluation 
of an authorised feed additive). EFSA received directly from the applicant the technical dossier in 
support of this application.
6 According to Article 8 of that Regulation, EFSA, after verifying the 
particulars and documents submitted by the applicant, shall undertake an assessment in order to 
determine whether the feed additive complies with the conditions laid down in Article 5. The 
particulars and documents in support of the application were considered valid by EFSA as of 1 March 
2011. 
The additive Rovabio
®  Excel  is  a  preparation  of  endo-1,3(4)-beta-glucanase  and  endo-1,4-beta-
xylanase produced by a strain of Penicillium funiculosum (IMI 378536, formerly IMI SD 101). The 
additive is currently authorised for use as a feed additive for chickens
7 and turkeys for fattening, laying 
hens,
8 ducks, weaned piglets,
9 and pigs for fattening.
10 The Scientific Committee on Animal Nutrition 
(SCAN) issued an opinion on the use of Rovabio
® Excel as a feed additive for pigs for fattening, 
chickens for fattening, laying hens and turkeys for fattening (EC, 1996 updated in 2002). Two other 
opinions were adopted by SCAN one on the safety of the product for weaned piglets and another one 
on the safety of the product for piglets (weaned) (EC, 2003a, and 2003b). The additive has not been 
previously assessed by EFSA. 
TERMS OF REFERENCE 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety for the target animals, consumer, user and the environment and the efficacy of the product 
                                                       
4  Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
5  ADISSEO, 10 Place du Général de Gaule, 92160 Antony, France. 
6  EFSA Dossier reference: FAD-2010-0189. 
7  Commission Regulation (EC) No 1259/2004 of 8 July 2004 concerning the permanent authorisation of certain additives 
already authorised in feedingstuffs. OJ L 293, 9.7.2004, p. 8. 
8  Commission Regulation (EC) No 943/2005 of 21 June 2005 concerning the permanent authorisation of addi tives in 
feedingstuffs. OJ L 159, 22.6.2005, p. 6. 
9  Commission Regulation (EC) No 322/2009 of 20 April 2009 concerning the permanent authorisation of certain additives in 
feedingstuffs. OJ L 101, 21.4.2009, p. 9. 
10 Commission Regulation (EC) No 1206/2005 of 27 July 2005 concerning the permanent authorisation of certain additives in 
feedingstuffs. OJ L 197, 28.7.2005, p. 12. Rovabio
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Rovabio
®  Excel  (endo-1,3(4)-beta-glucanase  and  endo-1,4-beta-xylanase),  when  used  under  the 
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Table 1:   Description and conditions of use of the additive as proposed by the applicant  
Additive   Endo-1,4 - xylanase EC 3.2.1.8 and Endo-1,3(4)-beta-glucanase EC 
3.2.1.6 
Registration number/EC No/No 
(if appropriate)  E1604 
Category(ies)  of additive  Zootechnical additive 
Functional group(s) of additive  Digestibility enhancer 
 
Description 
Composition, description  Chemical 
formula 
Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
 
Preparation of endo-1,4- 
beta-xylanase and endo-1,3(4)-beta-
glucanase and produced from 
Talaromyces versatilis  IMI 378536  
(basionym Penicillium funiculosum) 
having a minimum activity of: 
 
     Powder form (coated and not   
                       coated) 
- Endo-1,4-beta-xylanase: 
min. 22 000 viscometric units/g  
OR min.3 200 DNS units/g 
- Endo-1,3(4)-beta-glucanase : 
min 30 000 viscometric units/g 
OR min.4 300 DNS units/g 
                 
                  Liquid form 
- Endo-1,4-beta-xylanase: 
min. 5 500 viscometric units/ml OR 
min 800 DNS units/ml 
- Endo-1,3(4)-beta-glucanase : 
min 7 500 viscometric units/ml 
OR min. 1 075 DNS units/ml 
 
      Liquid form (concentrated) 
- Endo-1,4-beta-xylanase: 
min. 11 000 viscometric units/ml 
OR min 1600 DNS units/ml 
- Endo-1,3(4)-beta-glucanase: 
min. 15 000 viscometric units/ml 
OR min 2175 DNS units/ml 
 
/  / 
(short description) 
 
- Viscosimetric 
method: based on 
decrease in viscosity 
produced by action of 
Endo-1,4-xylanase on 
xylan containing 
substrate and action of 
Endo-1,3(4)-beta-
glucanase on glucan 
substrate. 
 
 Colorimetric (DNS) 
method: based of the 
enzymatic hydrolysis of  
xylan containing 
substrate and glucan 
substrate respectively 
for Endo-1,4 xylanase 
and  Endo-1,3(4)-beta-
glucanase 
 
 
 
Trade name (if appropriate)  ROVABIO® EXCEL 
Name  of  the  holder  of 
authorisation (if appropriate)  ADISSEO France S.A.S. 
 
Conditions of use 
Species  or 
category  of 
animal 
Maximum Age 
Minimum content  Maximum content  Withdrawal 
period 
(if appropriate) 
mg or Units of activity or CFU/kg of complete 
feedingstuffs  (select what applicable) 
All major and 
minor poultry  /  Endo-1,3(4)-
betaglucanase:  /  / Rovabio
® Excel for poultry and pigs 
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species, 
piglets 
(weaned), 
pigs for 
fattening 
1500 viscometric 
Units 
 
Endo-1,4-betaxylanase: 
1100 viscometric 
Units 
 
Other provisions and additional requirements for the labelling 
Specific  conditions  or  restrictions 
for use (if appropriate) 
In the directions for use of the additive and premixture, indicate the 
storage temperature, storage life, and stability to pelleting.   
Specific  conditions  or  restrictions 
for handling (if appropriate)  Do not breath, avoid contact with skin and eye 
Post-market monitoring  
(if appropriate) 
There is no need for specific requirements for a post-market 
monitoring  plan  other  than  those  established  by  Regulations  No 
178/2002 and No 183/2005. 
 
ADISSEO  has  a    full    traceability  system  in  place,  including 
procedures for recalls. A free emergency contact number is printed in 
each  label  and  also  available  in  the  Material  Safety  Data  Sheet 
supplied to all customers. 
   
Specific  conditions  for  use  in 
complementary feedingstuffs  
(if appropriate) 
For use in feed rich in strach and  non-starch polysaccharides 
(mainly beta-glucans and arabinoxylans) 
 
Maximum Residue Limit (MRL) (if appropriate) 
Marker residue  Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content 
in tissues 
/  /  /  / Rovabio
® Excel for poultry and pigs 
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ASSESSMENT 
1.  Introduction 
The additive Rovabio
® Excel is a preparation of endo-1,3(4)-beta-glucanase (EC 3.2.1.6; glucanase) 
and endo-1,4-beta-xylanase (EC 3.2.1.8; xylanase) which is available in solid and liquid forms. The 
enzymes are produced by a non-genetically modified strain of Penicillium funiculosum (Talaromyces 
versatilis sp. nov.; IMI CC 378536). A solid and a liquid formulation of the additive are currently 
authorised for use as a feed additive for chickens and turkeys for fattening, laying hens, ducks, weaned 
piglets and pigs for fattening. The applicant requested that the additive be re-evaluated for use in these 
species/categories and that its use in feed be extended to guinea fowls, quails, geese, pheasants and 
pigeons. Rovabio
® Excel is to be classified as a zootechnical additive under the functional group of 
digestibility enhancers. 
2.  Characterisation 
2.1.  Characterisation of the product 
This  additive  is  available  in  solid  and  liquid  forms.  The  additive  contains  two  main  enzymatic 
activities, glucanase and xylanase, but it also contains endo-1,4-beta-glucanase (EC 3.2.1.4) as a side 
activity. No details on the relevance of this side activity have been provided. The analysis of the main 
enzyme activities in the additive is performed following two methods, a viscosimetric-based method 
(viscosimetric  units  (U))  and  one  based  on  the  colour  formation  of  released  sugar  with  3,5-
dinitrosalicylic acid (DNS U). For details on the expression of the units, please see Appendix. 
The solid forms are an uncoated powder (Rovabio
® Excel AP) and a coated powder form (Rovabio
® 
Excel AP T-Flex). Rovabio
® Excel AP contains 15–25 % enzyme concentrate and 75–85 % wheat 
flour; Rovabio
® Excel AP T-Flex contains 15–25 % enzyme concentrate, 5–35 % wheat flour, 35–
45 % carboxymethyl cellulose and 0–40 % calcium carbonate. The ingredients used to formulate the 
product  are  food  or  feed  grade.
11  These two forms ensure  that,  per gram of product ,  there is  a 
minimum of  30 000 viscosimetric U or 4 300 DNS U of  glucanase and 22 000 viscosimetric U or 
3 200 DNS U of xylanase. 
The batch-to-batch variation of  Rovabio
® Excel AP and AP T-Flex was analysed in five batches.
12 
Rovabio
® Excel AP showed mean values of glucanase of 56 243 viscosimetric U/g (coefficient of 
variation  (CV)  4.7 %)  and  6 171  DNS  U/g  (CV  4 %)  and  mean  values  of  xylanase  of  30 840 
viscosimetric U/g (CV 5.2 %) and 3 802 DNS U/g (CV 2.5 %). Rovabio
® Excel AP T-Flex showed 
mean values of glucanase of 62 069 viscosimetric U/g (CV 4.2 %) and 6 871 DNS U/g (CV 3.5 %) 
and mean values of xylanase of 37 872 viscosimetric U/g (CV 3.8 %) and 4 401 DNS U/g (CV 3.4 %). 
The solid formulations have a clear light-beige colour with a particle size distribution (three batches of 
Rovabio
® Excel AP) showing not more than 5 % of the particles below 100 µm, and 0 % below 
30 µm.
13 It is assumed that  the coated form has a higher particle size. Dusting potential  was not 
provided. 
The liquid forms are  Rovabio
® Excel LC and a double concentrated form named  Rovabio
® LC2. 
Rovabio
®  Excel  LC  contains  4–8 %  enzyme  concentrate,  10–30 %  sorbitol,  0.1–0.4 %  potassium 
sorbate  and  water  up  to  100 %.  The  ingredients  used  to  formulate  the  product  are  food  grade.
14 
Rovabio
® Excel LC2 contains 8–16 % enzyme concentrate. The LC form ensures a minimum of 7 500 
                                                       
11 Technical dossier/Supplementary information December 2012. 
12 Technical dossier/Supplementary information December 2012/Annex iii.1. 
13 Technical dossier/Section II/Annex II.11. 
14 Technical dossier/Supplementary information December 2012. Rovabio
® Excel for poultry and pigs 
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viscosimetric U/mL or 1 075 DNS U/mL for the glucanase and 5 500 viscosimetric U/mL or 800 DNS 
U/mL for the xylanase and the LC2 formulation ensures double this.
15 
The batch-to-batch variation of the Rovabio
® Excel LC was analysed in five batches. Mean values 
obtained  for  glucanase  were  10 488  viscosimetric  U/mL  (CV  5.1 %)  and  1 181 DNS  U/mL  (CV 
3.4 %)  and mean values for xylanase were  6 529 viscosimetric U/mL (CV 4.3 %) and 920 DNS 
U/mL  (CV  4.8 %).  For  Rovabio
®  LC2,  five  batches  were  analysed;  mean  values  obtained  for 
glucanase were 21 399 viscosimetric U/mL (CV 6.1 %) and 2 609 DNS U/mL (CV 1.2 %) and for 
xylanase were 13 135 viscosimetric U/mL (CV 3.1 %) and 1 837 DNS U/mL (CV 7.0 %).
16 The liquid 
formulations have a colour from light to dark beige, with a pH ranging  from 3.8 to 4.3, a specific 
gravity of 1.1 at 20 °C and a viscosity of 3.2 mPa/s (data provided for the LC formulation).
 17 
Three batches of the fermentation concentrate used to prepare the formulations and three batches of 
Rovabio
® Excel AP and LC were analysed for chemical and microbial contamination.
18 Chemical 
contamination included the analysis of  lead (< 0.05 mg/kg), heavy metals (< 10 mg/kg) and arsenic 
(< 0.1 mg/kg). Microbial contamination analysis included  total viable counts (< 400 colony-forming 
units (CFU)/g or mL) total coliforms, moulds and yeasts (< 10 CFU/g in the solid and 1 CFU/ mL in 
the liquid formulation), Escherichia coli (< 1 CFU/g or mL) and absence of Salmonella spp. in 25 g. 
The  samples  were  also  analysed  for  aflatoxin  B1,  B2,  G1  and  G2  (< 0.01 µg/kg),  ochratoxin 
(< 0.2 µg/kg) and sterigmatocystin and zearalenone (< 10 µg/kg, one sample of the LC showed a value 
for zearalenone of 19 µg/kg). Evidence of the absence of antimicrobial activity and of the production 
strain was also provided. 
2.2.  Manufacturing process 
The  enzymes  contained  in  Rovabio
®  Excel  are  produced  by  a  non-genetically  modified  strain  of 
Penicillium funiculosum (Talaromyces versatilis sp. nov.)
19 deposited at CABI Bioscience UK with 
the IMI CC number 378536 (former deposit number IMI SD 101).
20 Data on the genetic stability of 
the strain  were provided (checked with  multilocus sequence typing (MLST) and polymerase chain 
reaction (PCR)-based methods).
21 The active substance is obtained by submerged fermentation of  the 
production strain. After the fermentation process, the broth is filtrated to separate the biomass from the 
supernatant and the filtrate is concentrated by ultrafiltration. Th e fermentation product obtained,  
Rovabio
® Bruxel SD, is used to prepare the powder and liquid formulations. 
2.3.  Stability and homogeneity 
2.3.1.  Shelf-life 
The shelf-lives of the different formulations were provided (three batches for each formulation, two 
for the LC2). The samples were kept for at least 12 months in closed containers at 20 or 35 °C. The 
enzyme activities were measured as DNS units for glucanase and as viscosimetric units for xylanase.
 22 
For  the  solid  formulations  (Rovabio
®  Excel  AP/Rovabio
®  Excel  AP  T-flex),  after  12  months  of 
storage, mean recoveries of glucanase were above 93 % or ~100 % when kept at 20 °C and were 
above 82/88 % when kept at 35 °C. Xylanase recoveries were above 82/83 % when samples were kept 
at 20 °C and above 77/74 % when kept at 35 °C.
 
                                                       
15 Technical dossier/Supplementary information December 2012. 
16 Technical  dossier/Supplementary  information  December  2012/Annex  iii.1  and  Supplementary  information  May 
2013/Annex ii.1. 
17 Technical dossier/Section II/Annex II.11. 
18 Technical dossier/Section II/Annex II.4a to 4m. 
19 Technical dossier/Supplementary information December 2012/Annex i.2. 
20 Technical dossier/Section II/Annex II.12 to II.14. 
21 Technical dossier/Supplementary information December 2012/Annex i.1. 
22 Technical dossier/Section II/Annexes II.27 and II.28 and supplementary information December 2012/Annexes iv.1 and 
iv.2. Rovabio
® Excel for poultry and pigs 
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For the liquid formulations (Rovabio
® Excel LC/Rovabio
® Excel LC2), after 12 months of storage, 
mean recoveries of glucanase were above 94/92 % when kept at 20 °C and were above 56/58 % when 
kept at 35 °C. Xylanase recoveries were above 72/79 % when samples were kept at 20 °C and above 
28/25 % when kept at 35 °C.
 After four months of storage at 35 ºC, mean recoveries for glucanase 
were above 72/79 % and for xylanase were above 50/54 %. 
2.3.2.  Stability of the additive in premixtures and feedingstuffs 
The  stability  of  the  solid  formulations  in  a  premixture  for  chickens  for  fattening  (complete  and 
containing choline chloride) was studied in three batches of each formulation for six months at two 
temperatures (20 and 30 ºC).
23 The mean supplementation was 85 DNS U/g for glucanase and 375 
viscosimetric U/g for xylanase. For Rovabio
® Excel AP, after six months, recovery values at 20 and 
30 °C, respectively, were above 95 % and 49 % for glucanase and above 83 % and 13 % for xylanase. 
For Rovabio
® Excel AP T-Flex, recovery values at 20 and 30 °C, respectively, were about 100 % and 
above 57 % for glucanase and above 84 % and 36 % for xylanase. The stability of one batch of the 
Rovabio
® Excel AP T-Flex when added to a complete premixture for sows (mean 39 DNS U/g for 
glucanase  and  250  viscosimetric  U/g  for  xylanase)  was  investigated  for  six  months  at  two 
temperatures (25 and 30 °C). The recovery values at 25 and 30 °C, respectively, were 96 % and 92 % 
for glucanase and 86 % and 69 % for xylanase.
24 
The stability of the solid formulations when added to feed was investigated in different feeds. In a first 
study,
25 Rovabio
® Excel AP was added to mash feed for laying hens and for pigs (three batches in 
each situation) at the recommended use levels and the stability was investigated for up to six months at 
three  different  temperatures:  20,  30  and  40 °C.  Recoveries  measured  as  viscosimetric  units  for 
xylanase after three months were above 71 % at 20 °C, above 66 % at 30 °C and above 50 % at 40 °C. 
Glucanase  was  not  evaluated  at  all  the  temperatures,  but  the  available  values  indicate  that  the 
recoveries (in viscosimetric units) were in all cases above 96 %. 
In a second study, the two solid formulations were added to a feed for chickens for fattening.
26 The 
mash feed was pelleted (conditioning at 70 ºC) and the study of the stability was conducted for three 
months at 20 or 30 ºC. Pelleting provoked a reduction in glucanase of 8 % and in xylanase of 10 % in 
the AP formulation and a reduction in glucanase of 13 % and in xylanase of 7 % in the AP-T Flex 
formulation. Recoveries of glucanase after three months were about 100 % at 20 ºC and above 88 % at 
30 ºC in mash feed contain ing either formulation; recoveries in the pelleted feed were higher than 
82 % at  both temperatures.  Recoveries  of  xylanase after three months,  measured as viscosimetric 
units,  were  about  100 % at  20 ºC and  above  80 % at  30 ºC in mash feed   in either formulation; 
recoveries in the pelleted feed were above 90 % at both temperatures. 
Finally, the applicant submitted a stability study conducted on a feed for sows based on wheat, barley 
and soya bean meal.
27 The additive (AP T-flex formulation) was added to mash and pelleted feed at 
the recommended dose. Samples of the supplemented feeds were kept at 25 or 30 °C for three months. 
The results showed that the recovery for glucanase was above 95 % at 25 °C and above 86 % at 30 °C; 
no losses were found for xylanase whe n kept at 25 °C and recovery was above 89 % when kept at 
30 °C. 
The liquid formulation, Rovabio
® Excel LC, was added to crumbled feed for laying hens and to 
pelleted  feed  for  turkeys  for  fattening  and  for  pigs  (three  batches  in  each  situation)  at  the 
recommended use levels and the stability was investigated for up to six months at three different 
temperatures: 20, 30 and 40 °C.
28 The results showed that, after three months, xylanase (measured as 
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viscosimetric units) recoveries were above 88 % at 20 °C, above 61 % at 30 °C and above 41 % at 
40 °C. Glucanase was not evaluated at all the temperatures, but the available values indicate that the 
recoveries (measured as viscosimetric units) were, in all cases, above 90 % (except in one sample, in 
which recovery was 48 %). 
A stability study limited to xylanase contained in the liquid formulation was also conducted in mixed 
duck feed (based on wheat and barley)
29 and the results showed that the enzyme retained its activity 
(measured by the viscosimetric method) over a period of more than one year. 
In a further study, the stability of the LC form was checked in a feed for chickens for fattening at two 
temperatures, 20 or 30 ºC, for three months. The results showed that the enzyme activities were not 
modified over time.
30 
2.3.3.  Homogeneity 
The capacity of homogeneous distribution of the enzyme formulations was studied in the samples 
subject to the stability studies. 
The  evaluation  of  10  sub-samples  in  a  premixture  for  chickens  for  fattening  supplemented  with 
Rovabio
® Excel AP or AP T-Flex showed, in all cases, a CV below 8 %.
31 A CV below 4.2 % was 
obtained in  10  sub-samples of a premixture  intended  to be incorporated in feed for sows and 
supplemented with Rovabio
® Excel AP T-Flex.
 32 
The  applicant  reported  the  homogeneity  of  the  two  solid  formulations  when  added  at  the 
recommended use levels to mash and pelleted feed for chickens (10  sub-samples).
33 The CV was 
below 10 % for glucanase and below 7 % for xylanase (mean: 2 500 viscosimetric U for glucanase and 
1 350  viscosimetric  U  for  xylanase).  The  homogeneity  of  distribution  in  feed  for   sows  was 
investigated with the AP T-Flex formulation in mash and pelleted feed (10  sub-samples); the results 
showed the  CV  was  below  8 %  for  glucanase  and xylanase (mean:  2 000  viscosimetric U/kg  for 
glucanase and 900 viscosimetric U/kg for xylanase). 
The homogeneous distribution of the liquid formulation was studied in a feed for chickens for 
fattening when added at the recommended  dose and the resulting CV was below 3 % (mean: 2 054 
viscosimetric U/ kg for glucanase and 1 185 viscosimetric U/ kg for xylanase). 
2.4.  Conditions of use 
The additive is proposed to be used in feed for chickens and turkeys for fattening, laying hens, piglets 
(weaned), pigs for fattening, ducks, guinea fowls, quails, geese, pheasants and pigeons at a dose of 
1 500 glucanase and 1 100 xylanase U/kg feed (measured as viscosimetric units). 
2.5.  Evaluation of the analytical methods by the  European Union Reference Laboratory 
(EURL) 
EFSA has verified the EURL report as it relates to the methods used for the control of the active 
substances in animal feed. The Executive Summary of the EURL report can be found in the Appendix. 
                                                       
29 Technical dossier/Section II/Annex II.31b. 
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33 Technical dossier/Section II/Annex II.31c and II.31d and supplementary information December 2012/Annex vi.2. Rovabio
® Excel for poultry and pigs 
 
EFSA Journal 2013;11(7):3321  12 
3.  Safety 
3.1.  Safety for the target species 
3.1.1.  Chickens for fattening 
A total of 1 080 one-day-old male chicks (Ross PM) were distributed in 72 pens of 15 birds each and 
allocated to three dietary treatments (24 replicates per treatment).
34 The basal diets (starter and grower) 
based  on  wheat  and  soy a  bean  meal  was  supplemented  with  Rovabio
®  Excel  AP  to  provide 
glucanase/xylanase  at  0/0,  3 000/2 200  (2×  recommended  dose)  or  300 000/220 000  (200×) 
viscosimetric U/kg feed. The enzyme activities were confirmed by analysis. The feed was offered to 
the birds ad libitum as crumble (starter: 0–21 days) or as pellets (grower: 22–35 days) for 35 days. The 
diets presented monensin. Feed consumption and body weight were measured on days 21 and 35 of 
the study. An analysis of variance (ANOVA) was performed on the data obtained (including treatment 
and block as effects). Mortality data were studied using a non-parametric test. 
Mortality was low (< 3.5 %) and not affected by the dietary treatments. Mean daily feed intake was 
110 g and the mean final body weight of the birds was 2.30 kg, both of which were not modified by 
the dietary treatments. The feed to gain ratio was improved by enzyme supplementation (1.73, 1.70 
and 1.67 for the 0, 2× and 200× groups, respectively). Supplementation of the experimental diets with 
200-fold the recommended dose did not have negative effects on the performance of the birds. 
3.1.2.  Turkeys for fattening 
A  total  of  1 200  one-day-old  male  and  female  chicks  (Grademakers  strain)  were  distributed  (sex 
separated) in 48 pens of 25 birds each and allocated to three dietary treatments (16 replicates per 
treatment, eight with males and eight with females).
35 The basal diets (starter and grower) based on 
wheat,  barley  and  soybean  meal  were  supplemented  with  Rovabio
®  Excel  AP  to  provide 
glucanase/xylanase  at  0/0,  3 000/2 200  (2×  recommended  dose)  or  300 000/220 000  (200×) 
viscosimetric U/kg feed. The enzyme activities were confirmed by analysis. The feed was offered to 
the birds ad libitum as crumble (starter: 0–21 days) or as pellets (grower: 22–42 days) for 42 days. All 
diets contained monensin. Feed consumption and body weight of the birds was measured on days 21 
and 42 of the study. An ANOVA was performed on the data obtained (initial body weight was used as 
a covariate). The effect of sex and the interaction with the treatment were also considered. 
Mortality was low (< 3.5 %) and not affected by the dietary treatments. Mean daily feed intake was 
77 g and mean final body weight of the birds was 1.80 kg, the feed intake and body weight in the 200× 
group being higher than in the control group (75 g vs. 79 g and 1.77 kg vs. 1.89 kg for the feed intake 
and body weight, respectively). The mean feed to gain ratio was 1.84, the value in the 200× group 
being lower than in the control group (1.86 vs. 1.81). Supplementation of the experimental diets with 
200-fold the recommended dose did not have negative effects on the performance of the birds. 
3.1.3.  Laying hens 
A total of 300 17-week-old hens (Lohman Brown Lite) were distributed in 60 floor pens of five birds 
each and allocated to three dietary treatments (20 replicates per treatment).
36 From week 17 to week 
21, the hens were fed a commercial layer diet. The basal diet , based on wheat, barley and soybean 
meal, was supplemented with Rovabio
® Excel AP to provide glucanase/xylanase at 0/0, 3 000/2 200 
(2× recommended dose) or 30 000/22 000 (20×) viscosimetric U/kg feed. The enzyme activities were 
confirmed by analysis. The feed was offered in mash form and ad libitum for 56 days. Body weight of 
the hens, laying performance and mortality and general health status were measured/monitored during 
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the study. Egg yolk colour was studied. At the end of the 56 days, blood samples from 10 birds per 
treatment were collected and analysed for total leucocyte count, total erythrocyte count, haemoglobin 
concentration, mean cell volume, platelet count, differential leucocyte count, glucose, total protein, 
albumin, albumin–globulin ratio, calcium, phosphorus, chloride, sodium, potassium, creatinine, urea, 
total bilirubin and activity of alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase, 
alanine aminotransferase and gamma-glutamyl transpeptidase. An ANOVA was performed on the data 
obtained. 
No hens died. No differences between the dietary treatments were found in the laying performance of 
the hens, mean daily feed intake was 118 g, mean laying rate was 97 %, mean egg mass production 
was 55 g per hen per day and mean feed to egg ratio was 2.12. Egg yolk colour did not differ between 
treatments.  Haematology  revealed  no  differences  between  the  experimental  treatments,  and  blood 
chemistry indicated only a decrease in the sodium in the 20× dose compared with the other two diet 
groups  (from  151  to  149 mmol/L).  Supplementation  of  the  experimental  diets  with  20-fold  the 
recommended dose did not have negative effects on the birds. 
3.1.4.  Safety for piglets 
A  total  of  135  castrated  male  piglets  (Youna   Piétrain,  21-day-old,  7–8 kg  body  weight)  were 
distributed randomly in a total of 45 floor pens in groups of three piglets and allocated to three dietary 
treatments (15 replicates per treatment).
37 From day 21 to day 28 of life , piglets were fed a post -
weaning adaptation diet (medicated feed) and the experimental diets were offered from day 28 of life. 
Two basal diets (pre-starter and starter), based on wheat, barley and soybean meal, were supplemented 
with Rovabio
® Excel AP to provide glucanase/xylanase at 0/0, 3 000/2 200 (2× recommended dose) or 
300 000/220 000 (200×) viscosimetric U/kg feed. The enzyme activities were confirmed by analysis. 
The feed was offered in pelleted form and ad libitum for 42 days. Body weight and feed intake were 
measured on day 14 and day 42 of the study (body weight was also measured at the beginning). An 
ANOVA was performed on the data obtained. The model included the effect of the diet, the room, 
block and the interaction between diet and room. The initial body weight at 28 days of age was used as 
a covariate. 
No piglets died. There were no significant differences between room and diets and no interaction 
between the diet and the room. Mean daily feed intake was 940 g, mean final body weight was 32 kg 
and mean feed to gain ratio was 1.59. Supplementation of the experimental diets with 200-fold the 
recommended dose did not have negative effects on the performance of the piglets. 
3.1.5.  Safety for pigs for fattening 
No specific study was provided to demonstrate the tolerance of pigs for fattening. The FEEDAP Panel 
considers that conclusions reached in piglets can be extended to pigs for fattening, provided that the 
same maximum dose applies. 
3.1.6.  Conclusions on the safety for the target species 
In the tolerance trials provided in chickens and turkeys for fattening, laying hens and piglets, the 
animals  tolerated  well  200-fold  (chickens,  turkeys  and  piglets)  or  20-fold  (laying  hens)  the 
recommended dosage. Therefore, the FEEDAP Panel concludes that the additive is safe for these 
target species at the recommended dose. The conclusion can be extended to pigs for fattening provided 
that the same dose applies. 
Considering the margin of safety demonstrated in major poultry species, the conclusions on the safety 
for these species can be extrapolated to ducks, guinea fowls, quails, geese, pheasants and pigeons. 
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3.2.  Safety for the consumer 
The toxicological studies reported under this section were performed on the fermentation product used 
for the formulated products, named Rovabio
® Bruxel SD. 
3.2.1.  Genotoxicity studies 
3.2.1.1.  Bacterial reverse mutation assay 
Rovabio
®  Bruxel  SD  was  tested  in  two  independent  experiments,  with  and  without  a  metabolic 
activation system (the S9 mix) prepared from a liver post-mitochondrial fraction (S9 fraction) of rats 
induced  with  Aroclor  1254,  in  compliance  with  the  OECD  Guideline  471  (1997).
38  The plate 
incorporation method was used except for the second test with  the S9 mix, which was performed 
according to the pre -incubation method (60 minutes, 37  °C).  Rovabio
®  Bruxel  SD  was  tested  on 
Salmonella Typhimurium, strains TA1535, TA1537, TA98, TA100 and TA102, up to a maximum 
dose of 5 000 µg/plate, which resulted in it being freely soluble and non-cytotoxic. The test item did 
not induce any noteworthy increase in the number of revertants in any of the five strains, in any 
experiment, either with or without S9 mix, while the positive controls performed as expected. 
3.2.1.2.  In vitro mammalian micronucleus test 
The investigation of the genotoxic activity of Rovabio
® Bruxel SD was carried out using an in vitro 
mammalian cell micronucleus test on cultured human lymphocytes, with and without the S9 mix from 
Aroclor 1254-induced livers (OECD 487, 2010).
39 Four independent experiments were performed:  a 
four-hour treatment and  a 24-hour recovery period without  the S9 mix (repeated twice);  the same 
schedule but with the S9 mix; and a 24-hour treatment and no recovery period without the S9 mix. 
A statistically significant increase in the frequency of micronucleated binucleated cells was observe d 
only at the highest concentration (10 %) in both four-hour experiments without the S9 mix. However, 
the tested concentration was much higher than the top level recommended by OECD Guideline 487 
(5 mg/mL) and produced an excessive cytotoxicity (≥ 64 % cytostasis); therefore, this result is not 
considered an indication of genotoxicity. No other statistically significant increase in micronuclei was 
found. 
3.2.1.3.  Mammalian erythrocyte micronucleus test 
The potential in vivo clastogenic activity of Rovabio
® Bruxel SD was tested using a micronucleus test 
in rat bone marrow, in compliance with the OECD Guideline 474 (1997).
40 Male and female Sprague–
Dawley OFA strain rats (five per sex per dosage group) were treated orally twice at 24-hour intervals 
with 2 000 mg/kg, followed by one sampling time 24 hours after the last treatment. No statistically 
significant increase in the frequencies of micronucleated polychromatic erythrocytes was found in the 
treated  animals  when  compared  with  the  untreated  controls.  The  ratio  of  polychromatic  to 
normochromatic erythrocytes was established at the highest dose level studied and no statistically 
significant alteration in comparison with the negative control group was found; therefore, no proof of 
systemic exposure was evidenced. 
3.2.1.4.  Conclusions on genotoxicity 
The  enzyme  concentrate  used  for  the  preparation  of  Rovabio
®  Excel  gave  negative  results  in  a 
bacterial reverse mutation assay, in an in vitro micronucleus test in human lymphocytes and in an in 
vivo  micronucleus  test  in  rat  bone  marrow,  although  without  evidence  of  target  tissue  exposure. 
Therefore, the additive is considered not to be genotoxic. 
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3.2.2.  Sub-chronic oral toxicity study 
The oral toxicity of Rovabio
® Bruxel SD was tested in Sprague–Dawley rats receiving daily 0, 250, 
500 and 1 000 mg/kg body weight of the test item incorporated into their diet for 13 consecutive 
weeks  in  compliance  with  OECD  Guideline  408  (1998).
41  Clinical observations were performed 
before the first dosing and daily. A full clinical examination was performed once  a week. The study 
was conducted with the full range of observations required by the guideline, including functional and 
neurobehavioural parameters, body weight, food consumption, ophthalmology, haematology, clinical 
chemistry and urine analysis. All animals were euthanised on day 91. Selected organs were weighed, 
fixed and preserved at necropsy and examined histopathologically. 
No mortality, no clinical signs and no change in body temperature were observed. There was a 
statistically significant lower body weight from day 84 in males receiving  Rovabio
® Bruxel SD at 
500 mg/kg body weight per day and 1 000 mg/kg body weight per day. There was no change in body 
weight gain in females. In males receiving Rovabio
® Bruxel SD, during the first two weeks of the 
study there was a higher food consumption, but this was not dose dependent and it was no longer 
observable  from  the  third  week  onwards.  There  was  no  abnormality  at  the  ophthalmological 
examination. No change of toxicological relevance was observed in haematology and coagulation 
parameters. 
Higher  plasma  aspartate  aminotransferase  activity  and  statistically  significant  lower  plasma  total 
protein concentration was reported in males whatever the dose, but these changes were not associated 
with microscopic changes at histopathological examination. In females receiving Rovabio
® Bruxel SD, 
there  were  lower  plasma  creatinine  concentrations  and  statistically  significant  lower  plasma  total 
protein  concentrations  whatever  the  dose.  The  changes  in  plasma  creatinine  were  found  only  in 
females  and  the  renal  creatinine  clearance  was  not  affected.  The  changes  in  plasma  creatinine 
concentrations were not associated with microscopic changes at histopathological examination. There 
was a lower sodium concentration in urine in males receiving Rovabio
® Bruxel SD at 1 000 mg/kg 
body  weight  per  day  without  any  toxicological  significance.  There  was  a  lower  absolute  thymus 
weight  in  males receiving  the  test  item,  which  was  more  marked  in  males receiving  the  dose  of 
1 000 mg/kg  body  weight  per  day  which  was  not  reflected  in  the  relative  thymus  weight  or 
histopathology of the thymus. In females, there was no marked change in organ weight. There were 
“abnormal contents” and gas in the small and large intestines in a few animals receiving the test item 
whatever the dose, likely resulting from increased fermentation owing to the nature of the test item. 
Histopathological analysis revealed no treatment-related changes in male and female rats receiving 
Rovabio
® Bruxel SD at 1 000 mg/kg body weight per day. 
3.2.3.  Conclusions on the safety for the consumer 
The  fermentation  product  used  for  the  preparation  of  the  additive  gave  negative  results  for 
mutagenicity. The results obtained in a sub-chronic oral toxicity study raised no concerns regarding 
the product. Therefore, based on the toxicological studies performed with the fermentation product, 
the additive is of no concern regarding consumer safety. 
3.3.  Safety for the user 
3.3.1.  Skin and eye irritation 
Rovabio
®  Excel  AP  (uncoated  powder formulation) and  Rovabio
®  Excel  LC2  (most  concentrated 
liquid formulation) were tested for skin irritation and/or corrosion following a single, semi-occluded 
application to intact skin of the rabbit in accordance with OECD Guideline 404 (2002).
42 Three New 
Zealand White rabbits were used for each test item.  For the solid and liquid formulations,  0.5 g and 
0.5 mL of the test item, respectively, were applied to the skin of the animal. Semi-occlusive dressings 
held the test item in place for three minutes, one hour and four hours on the skin of the first animal and 
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for four hours for the two other animals. Any cutaneous lesion was evaluated approximately one hour, 
24 hours, 48 hours and 72 hours after removal of the dressing. No cutaneous change was seen in any 
animal. Therefore, under the experimental conditions adopted, Rovabio
® Excel AP and LC2 were 
found to be non-irritant to the skin of rabbits. 
Rovabio
®  Excel  AP  (uncoated  powder formulation) and  Rovabio
®  Excel  LC2  (most  concentrated 
liquid formulation) were tested for acute eye irritation in rabbit, according to OECD Guideline 405 
(2002).
43 Three New Zealand White rabbits  were used for each test item.  For the solid and liquid 
formulations, 0.1 g or 0.1 mL of the substance, respectively, was introduced into the conjunctival sac 
of the left eye of each of the animals. The untreated right eye served as a control. Any conjunctival, 
iris and corneal changes were evaluated approximately one hour, 24 hours, 48 hours and 72 hours after 
instillation. Except for lacrimation seen at  one  hour, no other ocular change was recorded after 
instillation. Therefore, under the experimental conditions adopted, Rovabio
® Excel AP and LC2 were 
found to be non-irritant to the eye of rabbits. 
3.3.2.  Conclusions on the safety for the user 
Two final formulations (Rovabio
® Excel AP and LC2) were tested for skin and eye irritation and both 
showed no evidence of dermal or eye irritation. The other two final formulations (AP T-Flex and LC) 
were not tested, but based on their composition their irritant potential is unlikely to be significantly 
different from that of their tested counterparts. 
In the absence of data on its skin sensitisation properties, and taking account of its proteinaceous 
nature, the additive is to be considered a potential skin and respiratory sensitiser. 
3.4.  Safety for the environment 
The active substances of Rovabio
® Excel are proteins, and as such will be degraded/inactivated during 
the passage through the digestive tract of animals. Therefore, no risks to the environment are expected 
and no further environmental risk assessment is required. 
4.  Efficacy 
In  some  of  the  experimental  feeds  used  in  the  efficacy  studies,  only  xylanase  was  measured. 
Glucanase activity was calculated from xylanase by applying a factor (1.72). This factor was based on 
experimental  data  which  demonstrated  an  acceptable  relationship  between  the  measured  and 
calculated viscosimetric units. Therefore, the calculations were accepted. 
4.1.  Efficacy for chickens for fattening 
Four long-term trials and one short-term trial were considered for the assessment. A summary of the 
experimental design of the long-term trials is presented in Table 2 and the relevant results are shown 
in Table 3. 
The duration of the four long-term trials was at least 35 days. The basal diets were supplemented with 
Rovabio
® Excel to provide glucanase/xylanase at 0/0 or 1 500/1 100 viscosimetric U/kg feed. Basal 
diets were based on wheat and soya bean meal in trials 1 to 3 and on wheat, soya bean meal and wheat 
dried  distiller  grains  with  solubles  in  trial  4.  Feed  was  offered  ad  libitum  in  pelleted  forms  and 
contained  coccidiostats.  Performance  was  measured  throughout  the  study  and  an  ANOVA  was 
performed with the data. 
Mortality rate was low and not affected by the dietary treatments. The supplementation of the diets 
with Rovabio
® Excel at the dose of 1 500/1 100 U/kg feed for glucanase/xylanase resulted in a higher 
final body weight in trial 3 and a better feed to gain ratio in the four trials compared with the control. 
                                                       
43 Technical dossier/Supplementary information December 2012/Annexes ix.3 and ix.4. Rovabio
® Excel for poultry and pigs 
 
EFSA Journal 2013;11(7):3321  17 
Table 2:   Trial design and dosage confirmation for the efficacy trials in chickens for fattening 
Trial  
Animal breed 
(age at start, sex)  
duration, days 
Total no animals 
(animals/replicate)  
replicates/treatment 
Form of the 
additive 
Feed enzyme activities 
 (glucanase/xylanase U/kg feed) 
Intended  Analysed
1 
1
44 
Ross 
 (day-old, ♀) 
42 
640 
(40) 
8 
LC  0/0 
1 500/1 100 
–/– 
1 775/1 032 
2
45 
Ross PM3 
 (day-old, ♂) 
42 
360 
(15)  
12 
AP  0/0 
1 500/1 100 
–/– 
1 622/982 
3
46 
Ross PM3 
 (day-old, ♂) 
35 
960 
(40)  
12 
AP  0/0 
1 500/1 100 
–/– 
2 038/1 266 
4
47 
Ross 308 
 (day old, ♂) 
38 
574 
(41)  
7 
LC  0/0 
1 500/1 100 
–/– 
1 779/966 
1  Values are means for starter and grower diets. In trial 1, values are calculated from the analysis of xylanase with an non-
viscosimetric method. 
Table 3:   Effect of Rovabio
® Excel on the performance of chickens for fattening 
Trial 
Intended dose 
glucanase/xylanase 
(U/kg) 
Feed 
intake
1 (g)  Final body weight 
(g) 
Feed to gain 
 ratio  Mortality (%) 
1  0/0 
1 500/1 100 
3 882 
3 796 
1 931 
1 954 
2.06
a 
1.99
b 
4.4 
6.9 
2  0/0 
1 500/1 100 
122 
119 
2 940 
2 935 
1.76
a 
1.73
b 
5.6 
3.9 
3  0/0 
1 500/1 100 
109 
109 
2 217
b 
2 273
a 
1.75
a 
1.72
b 
4.4 
2.9 
4  0/0 
1 500/1 100
 
124
a 
121
b 
2 778 
2 782 
1.72ª 
1.68
b 
4.9 
5.7 
1  Feed intake in trial 1 is total feed intake (42 days) and in the other trials it is daily feed intake. 
a,bMean values in one column and within one trial without a common superscript are different (P < 0.05). 
The short-term trial was a balance trial performed in male chicks (18 days old).
48 The results showed 
that the supplementation of a wheat -based diet with  the recommended dose of   Rovabio
®  Excel 
increased the apparent metabolisable energy (AME) content of the diet from 3 171 to 3 411 kcal/kg 
dry  matter  and  the  nitrogen-corrected  value  (AMEn,  calculated) from  3 068 to  3 306  kcal/kg  dry 
matter. 
The results from four trials show that the additive has the potential to be efficacious in chickens for 
fattening at the recommended dose. Additional support of efficacy is provided by the short-term trial. 
4.2.  Efficacy for turkeys for fattening 
Three long-term trials and one short-term trial were considered for the assessment. A summary of the 
experimental design of the long-term trials is presented in Table 4 and the relevant results are shown 
in Table 5. 
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46 Technical  dossier/Supplementary  information  December  2012/Annex  xv.2  and  supplementary  information  May 
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The duration of the three trials was at least 84 days. The basal diets were supplemented with Rovabio
® 
Excel to provide glucanase/xylanase at 0/0 or 1 500/1 100 viscosimetric U/kg feed. Basal diets were 
based on wheat, barley and soya bean meal. Diets were changed during the study according to the 
animal‟s requirement (three basal diets in trial 1 and four basal diets in trials 2 and 3). Feed was 
offered  ad  libitum  as  crumbles  in  the  first  stages  and  then  in  pelleted  form.  In  trial  1,  the  feed 
contained  coccidiostats.  Performance  was  measured  throughout  the  study  and  an  ANOVA  was 
performed with the data. 
Table 4:   Trial design and dosage confirmation for the efficacy trials in turkeys for fattening 
Trial  
Animal breed 
(age at start, sex) 
duration, days 
Total no animals 
(animals/replicate) 
replicates/treatment 
Form of 
the 
additive 
Feed enzyme activities 
(glucanase/xylanase U/kg feed) 
Intended  Analysed
1 
1
49 
BUT 9 
(day-old; ♀) 
84 
496 
(31–25)
2 
8 
AP  0/0 
1 500/1 100 
–/– 
2 406/1 399 
2
50 
BUT 9 
(day-old; ♀,♂) 
84 (♀) 140 (♂) 
1 000 
(25–8)
3 
20 
LC  0/0 
1 500/1 100 
–/– 
2 024/1 177 
3
51 
BUT 9 
(day-old; ♂) 
112 
320 
(20–12)
4 
8 
LC  0/0 
1 500/1 100 
–/– 
2 105/1 224 
1  In trial 1, xylanase recovery was expressed as mg additive/kg feed; units were calculated from the batch used. In the other 
trials, only xylanase viscosimetric units were measured. In all trials, glucanase viscosity activity was calculated (glucanase 
activity = 1.72   measured xylanase viscosity in feed).
 
2  Until day 28, there were 31 birds per replicate. From day 28 to day 84, there were 25 birds per replicate (the smallest and 
the heaviest were removed from the pens). 
3  Until day 84, there were 25 birds per replicate (males and females). From day 84 to day 140, there were eight birds per 
replicate (males only). 
4  Until day 56, there were 20 birds per replicate. From day 56 to day 112, there were 12 birds per replicate (birds removed to 
keep the mean live weight in each pen). 
The mortality rate was low and not affected by the dietary treatments. The supplementation of the 
diets with Rovabio
® Excel at the dose of 1 500/1 100 U/kg feed for glucanase/xylanase resulted in a 
higher final body weight in trial 2 and a better feed to gain ratio in the three trials compared with the 
control. 
Table 5:   Effects of Rovabio
® Excel in the performance of turkeys for fattening 
Trial 
Intended dose 
glucanase/xylanase 
(U/kg) 
Feed intake 
(g)
1 
Body weight
2 
(g) 
Feed to gain 
ratio 
Mortality 
(%) 
1  0/0 
1 500/1 100 
168 
161 
6 619 
6 658 
2.12
a 
2.02
b 
4.7 
4.8 
2
3  0/0 
1 500/1 100 
12 561/43 314 
12 613/42 631 
4 744/13 992 
4 840*/14 415*
 
2.65/3.10
 
2.61*/2.96*
 
0/0 
0/0.2 
3  0/0 
1 500/1 100 
29 400 
29 480 
12 767 
13 222 
2.31
a 
2.23
b 
8.1 
3.1 
1  Daily feed intake for trial 1, total feed intake for trials 2 and 3. 
2  Body weight in trial 1 and body weight gain in trials 2 and 3. 
3  Values in trial 2 are for females/males, respectively (females until day 84, males until day 140).
. 
a,bMean values in one column and within one trial without a common superscript are different (P < 0.05). 
* Mean values are different (P < 0.05) to the control group for a given sex. 
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The short-term trial was a balance trial performed in male turkeys (33 days old).
52 The results showed 
that the supplementation of a wheat -based diet with  Rovabio
®  Excel  (1 500  xylanase  U/kg  feed) 
significantly increased the apparent AMEn content of the diet from 3 025 to 3 150 Kcal/kg dry matter. 
Results from the long-term trials show that the additive has the potential to improve the performance 
of turkeys for fattening at the recommended dose. Results of the short-term trial support the potential 
of the additive. 
4.3.  Efficacy for laying hens 
Two long-term trials and three short-term trials were considered. 
4.3.1.  Long-term trials 
In the first trial, 480 laying hens (Hy-Line Brown), 21-week-old, were distributed into two dietary 
treatments in cages of five hens (each replicate consisting of three cages, 16 replicates per treatment).
53 
Hens were fed a diet based on wheat, barley and soya bean meal supplemented with Rovabio
® Excel 
LC  to  provide  glucanase/xylanase  at  0/0  or  1 500/1 100  viscosimetric  U/kg  feed.  Xylanase  was 
confirmed by analysis to be 1 248 U/kg (glucanase activity calculated). Diets were offered in mash 
form  until  week  48,  and  laying  performance  and  egg  quality  parameters  (also  including  eggshell 
breaking strength parameters and egg size distribution measured in three different weeks; data not 
shown) were measured throughout the experimental period. An ANOVA was performed with the data 
and results are presented in Table 6. 
Table 6:   Effect of Rovabio
® Excel on the laying performance of hens and the percentage of broken 
eggs 
Intended dose 
glucanase/xylanase 
(U/kg) 
Daily feed 
intake 
(g) 
Laying rate 
(%) 
Egg mass 
production 
(g/day) 
Feed to 
egg mass 
ratio 
Broken eggs 
(%)
 
0/0 
1 500/1 100 
103
a 
101
b 
92.8 
92.6 
54.6 
54.7 
1.89
a 
1.84
b 
0.68
a 
0.47
b 
a,bMean values in one column without a common superscript are different (P < 0.05). 
The  addition  of  Rovabio
®  Excel  at  the  recommended  dose  improved  the  feed  to  egg  mass  ratio 
compared with the control diet and decreased the number of broken eggs. Some modifications on the 
egg quality parameters were found but a clear tendency in the three measurements related to the 
treatments was not found. 
In the second trial,
54 200 laying hens (ISA Brown) , 21-week-old, were distributed into two dietary 
treatments in pens of five hens (20 replicates per treatment). Hens were fed a diet based on wheat, 
barley and soya bean meal supplemented with  Rovabio
® Excel LC to provide glucanase/xylanase at 
0/0 or 1 500/1 100 viscosimetric U/kg feed, confirmed by analysis (1 839/1 138 U/kg feed). Diets 
were offered for 24 weeks, and laying performance and egg quality parameters (egg yolk colour, egg 
shell weight, yolk and albumen; data not shown) were measured throughout the experimental period 
(performance) or at the end of the experiment (quality parameters). An ANOVA was performed with 
the data and results are presented in Table 7. 
A total of eight hens died or had to be removed from the study, no differences between the groups. 
The  addition  of  Rovabio
®  Excel  at  the  recommended  dose  improved  the  feed  to  egg  mass  ratio 
compared with the control diet. 
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Table 7:   Effect of Rovabio
® Excel on the laying performance of hens  
Intended dose 
glucanase/xylanase 
(U/kg) 
Daily feed 
intake 
(g) 
Laying rate 
(%) 
Egg mass production 
(g/day) 
Feed to egg mass 
ratio 
0/0 
1 500/1 100 
127 
126 
90.2 
92.5 
56.3 
57.4 
2.29
a 
2.21
b 
a,bMean values in one column without a common superscript are different (P < 0.05). 
4.3.2.  Short-term trials 
Two short-term trials were provided with the same design.
55 In each trial, 24 Isa Brown hens (26 - 
week-old) were distributed individually into two different dietary treatments (12 replicates per 
treatment). Diets  were  based on  barley,  maize  and soya bean meal  and  were supplemented with 
Rovabio
® Excel AP to provide glucanase/xylanase at 0/0 or 1 500/1 100 viscosimetric U/kg feed. 
Xylanase  was  confirmed  in  the  diets  (1 130  and  1 057  U/kg,  respectively)  and  glucanase  was 
calculated. The studies lasted for 14 days, with an adaptation period of nine days and a five-day 
collection  period.  Apparent  metabolisable  energy  of  the  diets  was  measured  and  the  AMEn  was 
calculated. 
Results showed that the addition of Rovabio
® Excel in the diets significantly increased the AMEn in 
the diets: in trial 1 from 2 949 to 3 033 kcal/kg feed and in trial 2 from 2 951 to 3 119 kcal/kg feed. 
A third short-term trial was performed with a similar design to the other two trials presented.
56 The 
results showed that Rovabio
® Excel at the recommended xylanase dose of 1 100 viscosimetric U/kg 
feed (glucanase activity not measured) significantly increased the AME from 2 682 to 2 748 kcal/kg 
feed (results on the AMEn not provided). 
The results from the long-term and short-term trials show that the additive has the potential to be 
efficacious in laying hens at the recommended dose.
 
4.4.  Efficacy for weaned piglets 
Five long-term trials were considered for the assessment. A summary of the experimental design is 
presented in Table 8 and the relevant results are shown in Table 9. 
The duration of the five trials was 42 days. The basal diets were supplemented with Rovabio
® Excel 
(solid form) to provide glucanase/xylanase at 0/0 or 1 500/1 100 viscosimetric U/kg feed in trials 2 to 
5, or 0/0, 1 500/1 100, 3 000/2 200 or 4 500/3 300 viscosimetric U/kg feed in trial 1. Basal diets were 
based on wheat, barley and soya bean meal in trials 1 to 4 and on wheat, rye and soya bean meal in 
trial 5. Feed was offered ad libitum in pelleted form for 42 days as a pre-starter (0–14 days) and a 
starter (14–42 days) diet. In all trials, the performance of the animals was measured throughout the 
study. 
Mortality was low. Trial 1 and trial 2 showed a significant positive effect on the performance of 
piglets at the recommended dosage. Data from trials 2–5 were pooled and a statistical analysis was 
carried out.
57 Trial 1 was not considered because the animals were individually housed. The data set , 
including feed intake,  final body weight, daily weight  gain and feed to gain ratio, was tested for 
homogeneity. Results showed a significantly higher body weight  (29.3 vs.  29.9 kg), significantly 
higher daily weight gain (523 vs. 540 g/day) and a significantly better feed to gain ratio (1.63 vs. 1.60) 
in the groups of animals receiving Rovabio
® Excel at the recommended dose  compared with the 
control  group.  Feed  intake  was  not  statistically  different  (846  vs.  864).  These  results  show  that 
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Rovabio
® Excel has the potential to improve the performance of piglets (weaned) at the recommended 
dose. 
Table 8:   Trial design and dosage confirmation for the efficacy trials in weaned piglets 
Trial  
Animal breed 
(age at start) 
 sex 
Total no animals 
(animals/replicate) 
replicates/treatment 
Feed enzyme activities 
(glucanase/xylanase U/kg feed) 
Intended  Analysed 
1,2 
1
58 
Piétrain × German 
Landrace  
(28 days) 
 ♂, ♀ 
48 
(1) 
12 
0/0 
1 500/1 100 
3 000/2 200 
4 500/3 300 
–/– 
2 997/1 731 
-/2 869 
-/3 812 
2
59 
Piétrain × German 
Landrace 
(30 days) 
♂ castrated, ♀ (mixed) 
232 
(28 or 30) 
4 
0/0 
1 500/1 100 
–/– 
2 668/1 551 
3
60 
Piétrain × Youna 
(28 days) 
♂castrated 
96 
(2) 
24 
0/0 
1 500/1 100 
–/– 
1 853/1 151 
4
61 
Piétrain × Youna  
(28 days) 
♂ castrated 
96 
(2) 
24 
0/0 
1 500/1 100 
–/– 
1 639/1 167 
5
62 
Talent × (Great 
Yorkshire × Finnish 
Landrace) 
(26 days) 
♂ castrated, ♀ (mixed) 
180 
(6) 
15 
0/0 
1 500/1 100 
–/– 
2 044/1 395 
1  In  trials  1  and  2,  only  xylanase  was  measured  in  the  experimental  feeds;  glucanase  viscosity  activity  was  calculated 
(glucanase activity = 1.72   measured xylanase viscosity in feed). In trial 1, data were not provided for glucanase activity 
in diets containing higher dosages than the minimum recommended dose. 
2  Values are the average enzyme activity of pre-starter (day 0 to day 14) and starter (day 14 to day 42) diets in trials 2–5. 
Table 9:   Effect of Rovabio
® Excel on the performance of weaned piglets 
1  In trial 4, values are culled animals. 
a,bMean values in one column and within one trial without a common superscript are different (P < 0.05). 
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Trial 
Intended dose 
glucanase/xylanase 
(U/kg) 
Daily feed intake 
(g) 
Body weight (kg)  Daily weight 
gain 
(g/day) 
Feed-to-
gain ratio 
Mortality 
(%)
1  Initial  Final 
1 
0/0 
1 500/1 100 
3 000/2 200 
4 500/3 300 
849 
869 
870 
856 
7.2 
7.2 
7.2 
7.3 
28.9 
30.2 
29.8 
29.9 
520 
550 
540 
540 
1.64
a 
1.59
b 
1.62
ab 
1.59
b 
0 
0 
0 
0 
2  0/0 
1 500/1 100 
803 
839 
10.1 
9.9 
29.3
b 
30.3
a 
460
b 
490
a 
1.75 
1.73 
1 
0 
3  0/0 
1 500/1 100 
1 004 
1 024  6.9  32.9 
33.8 
613 
634 
1.63 
1.61 
0 
1 
4  0/0 
1 500/1 100 
1 038 
1 020  7.2  33.2 
33.3 
627 
629 
1.66 
1.62 
1  
2 
5  0/0 
1 500/1 100 
639 
662  7.7  25.6 
26.1 
435 
454 
1.47 
1.46 
0 
1 Rovabio
® Excel for poultry and pigs 
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4.5.  Efficacy for pigs for fattening 
Three long-term trials were considered for the assessment. A summary of the experimental design is 
presented in Table 10 and the relevant results are shown in Table 11. 
In the three trials, the animals were studied for at least 74 days. The basal diets were supplemented 
with Rovabio
® Excel (liquid form in trial 1, solid form in trials 2 and 3) to provide glucanase/xylanase 
at 0/0 or 1 500/1 100 viscosimetric U/kg feed in trials 2 and 3, or 0/0, 1 500/1 100, 2 250/1 650 or 
22 500/16 500 viscosimetric U/kg feed in trial 1. Basal diets were based on wheat, barley and soya 
bean meal. Feed was offered in pelleted form in trial 1 and in mash form in trials 2 and 3 as grower 
and finisher diets (trial 2: only grower diet). The animals were fed “relatively close to ad libitum” in 
trial 1, restrictedly in trial 2 and ad libitum in trial 3. In all trials, the performance of the animals was 
measured throughout the study. 
No animals died. In trial 1, a positive effect of Rovabio
® on daily weight gain and on feed to gain ratio 
was observed at the intended glucanase/xylanase dose of 1 500/1 100 U/kg feed. In trial 2, Rovabio
® 
Excel improved final body weight and daily weight gain. In trial 3, feed to gain ratio was significantly 
improved at the recommended dose. 
Table 10:   Trial design and dosage confirmation for the efficacy trials in pigs for fattening 
Trial 
Animal breed 
(sex) 
duration, days 
Total no animals 
(animals/replicate) 
replicates/treatment 
Feed enzyme activities 
(glucanase/xylanase U/kg feed) 
Intended  Analysed
1,2 
1
63 
Piétrain x (Landrace × Large 
White) 
(♂castrates) 
> 74 days 
36 
(1) 
9 
0/0 
1 500/1 100 
2 250/1 650 
22 500/16 500 
– 
1 477/859 
–/1 175 
–/14 694 
2
64 
Landrace Yorkshire × Hampshire 
(♂ castrates, ♀) 
100 days 
96 
(2) 
24 
0/0 
1 500/1 100 
– 
1 729/1 005 
3
65 
SELPA Crossbred 
(♀) 
77 days 
40 
(1) 
20 
0/0 
1 500/1 100 
– 
2 114/1 229 
1  Only  xylanase  was  measured  in  the  experimental  feeds;  glucanase  viscosity  activity  was  calculated  (glucanase 
activity = 1.72   measured xylanase viscosity in feed). In trial 1, data were not provided for glucanase activity in diets 
containing higher dosages than the minimum recommended dose. 
2  Average enzyme activity of grower and finisher diets in trials 1 and 3. 
Table 11:   Effect of Rovabio
® Excel on the performance of pigs for fattening 
Trial 
Intended dose 
glucanase/xylanase 
(U/kg) 
Daily feed 
intake 
(kg) 
Body weight (kg)  Daily weight 
gain 
(kg/day)
 1 
Feed to gain 
ratio
1 
Mortality 
(%)  Initial  Final 
1 
0/0 
1 500/1 100 
2 250/1 650 
22 500/16 500 
2.3 
2.3 
2.3 
2.3 
30 
30 
31 
31 
103 
103 
103 
103 
0.94
b 
0.98
a 
0.97
ab 
0.98
a 
2.44
a 
2.33
b 
2.34
ab 
2.32
a 
0 
0 
0 
0 
2  0/0 
1 500/1 100 
– 
– 
26.4 
25.7 
115.1
b 
117.2
a 
0.89
b 
0.91
a 
2.76 
2.71 
0 
0 
3  0/0 
1 500/1 100 
2.2 
2.2 
30.5 
29.7 
95.7 
95.9 
0.85 
0.86 
2.63
b 
2.56
a 
0 
0 
1  In trial 1, data were adjusted for a same feed consumption and a same corporal composition (same lean meat content). 
a,bMean values in one column and within one trial without a common superscript are different (P < 0.05). 
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Three long-term trials showed a positive significant effect of Rovabio
® Excel on the performance of 
pigs for fattening at the recommended dose. 
4.6.  Conclusions on the efficacy 
Based on the results obtained in the efficacy trials provided in chickens and turkeys for fattening, 
laying hens, piglets (weaned) and pigs for fattening, the FEEDAP Panel concludes that the additive 
has the potential to be efficacious at the recommended dose. 
The mode of action of the enzymes glucanase and xylanase is well known and can be considered to be 
similar in all poultry species; thus, the conclusions on the efficacy in major poultry species can be 
extrapolated to ducks, guinea fowls, quails, geese, pheasants and pigeons. 
5.  Post-market monitoring 
The  FEEDAP  Panel  considers  that  there  is  no  need  for  specific  requirements  for  a  post-market 
monitoring  plan  other  than  those  established  in  the  Feed  Hygiene  Regulation
66  and  Good 
Manufacturing Practice. 
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
The solid and the liquid formulations are considered equivalent in terms of safety and efficacy for the 
target species, provided that the same dose in enzyme units applies. 
Based on the results obtained in tolerance trials performed in chickens and turkeys for fattening, laying 
hens and piglets, in which the animals tolerated well 200-fold (chickens, turkeys and piglets) or 20-
fold (laying hens) the recommended dosage, the FEEDAP Panel concludes that the additive is safe for 
these target species at the recommended dose. The conclusion can be extended to pigs for fattening 
provided that the same dose applies. Considering the margin of safety demonstrated in major poultry 
species, the conclusions on the safety for these species can be extrapolated to ducks, guinea fowls, 
quails, geese, pheasants and pigeons. 
The  fermentation  product  used  for  the  preparation  of  the  additive  gave  negative  results  for 
mutagenicity. The results obtained in a sub-chronic oral toxicity study raised no concerns regarding 
the product. Therefore, the additive does not give rise to any concern for consumer safety. 
Two formulations (Rovabio
® Excel AP and LC2) were tested for skin and eye irritation and showed no 
evidence of causing such effects. The other two formulations (AP T-Flex and LC) were not tested, but 
based on their composition, their irritant potential is unlikely to be significantly different from that of 
their tested counterparts. In the absence of data on its skin sensitisation properties, and taking account 
of its proteinaceous nature, the additive is to be considered a potential skin and respiratory sensitiser. 
The active substances of Rovabio
® Excel are proteins, and as such will be degraded/inactivated during 
the passage through the digestive tract of animals. Therefore, no risks to the environment are expected 
and no further environmental risk assessment is required. 
Based on the results obtained in the efficacy trials provided in chickens and turkeys for fattening, 
laying hens, piglets (weaned) and pigs for fattening, the FEEDAP Panel concludes that the additive 
has the potential to be efficacious at the recommended dose. The mode of action of the enzymes 
glucanase and xylanase is well known and can be considered to be similar in all poultry species. 
                                                       
66 Regulation  (EC)  No  183/2005  of  the  European  Parliament  and  of  the  Council  of  12  January  2005  laying  down 
requirements for feed hygiene. OJ L 35, 8.2.2005, p. 1. Rovabio
® Excel for poultry and pigs 
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Therefore, the conclusions on the efficacy in major poultry species  can be extrapolated to ducks, 
guinea fowls, quails, geese, pheasants and pigeons. 
RECOMMENDATION 
The FEEDAP Panel recommends the modification of the specifications of the product regarding the 
viscosimetric enzyme activity. The specifications should be modified by increasing the ratio of the two 
enzymes (glucanase to xylanase) in the additive from 1.36 to 1.76. This would result in an increase in 
the minimum specified content of glucanase to ~39 000 U/g in the solid formulations and to ~9 500 or 
19 000 U/g in the Rovabio
® Excel LC or LC2, respectively. This modification would better reflect the 
enzyme  concentration  found  in  the  product  (see  batch-to-batch  variation)  and  the  efficacious 
concentration  in  feed  (from  the  intended  dose  of  1 500/1 100  U/kg  feed  to  the  analysed  dose  of 
~1 900/1 100 U/kg feed). This recommendation is also supported by the data provided from the study 
of the extrapolation of the glucanase enzyme activity from data on measured xylanase activity. No 
recommendation is made on the DNS units as there is no link between those units and the units in 
feed. 
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APPENDIX  
Executive Summary of the Evaluation Report of the Community Reference Laboratory for Feed 
Additives on the Method(s) of Analysis for Rovabio
® Excel 
In the current application authorisation is sought under articles 4(1) and 10(2) for Rovabio Excel, 
under the category/functional group 4(a) "zootechnical additives"/"digestibility enhancers", according 
to the classification system of Annex I of Regulation (EC) No 1831/2003. According to the Applicant, 
the feed additive contains two active substances: endo-1,3(4)- -glucanase (EC 3.2.1.6) and endo-1,4-
-xylanase (EC 3.2.1.8), produced by the strain Penicillium funiculosum Pf 8/403 (IMI 378536). The 
product is intended to be marketed in different formulations as: (i) liquid (Rovabio Excel LC and 
Rovabio Excel LC2); and (ii) solid (non-coated: Rovabio Excel AP and coated: Rovabio Excel AP T-
FLEX). Liquid formulations have a guaranteed minimum endo-1,3(4)- -glucanase activity of 7500 
U/ml (  1075 DNS units/ml) and an endo-1,4- -xylanase activity of 5500 U/ml (  800 DNS units/ml). 
Solid formulations have a guaranteed minimum endo-1,3(4)- -glucanase activity of 30000 U/g (  
4300 DNS units/g) and an endo-1,4- -xylanase activity of 22000 U/g (  3200 DNS units/g).  
The activity of endo-1,3(4)- -glucanase and endo-1,4- -xylanase is expressed in viscosimetric unit 
(U): 
  one viscosimetric unit (U) is the amount of enzyme which hydrolyzes the substrate (barley 
betaglucan and wheat arabinoxylan, respectively), reducing the viscosity of the solution, to 
give a change in relative fluidity of 1 (dimensionless unit)/min at 30 
oC and pH 5.5.  
Alternatively, the activity of endo-1,3(4)- -glucanase and endo-1,4- -xylanase is expressed in DNS 
units (U): 
  For glucanase, one "DNS unit" is the amount of enzyme which hydrolyzes the substrate barley 
betaglucan producing 1 μmole of glucose per minute at pH 5.0 and 50  °C;  
  For xylanase, one "DNS unit" is the amount of enzyme which hydrolyzes birchwood xylan 
producing 1 μmole of xylose per minute at pH 4.0 and 50 °C. 
Specifically, authorisation is sought for the use of Rovabio Excel for laying hens, turkeys for fattening, 
chickens for fattening, pigs for fattening, weaned piglets, ducks, guinea fowls, quails, geese, pheasants 
and  pigeons.  The  feed  additive  is  intended  to  be  incorporated  into  premixtures  and/or  complete 
feedingstuffs with a minimum activity of 1100 U endo-1,4- -xylanase/kg and 1500 U endo-1,3(4)- -
glucanase/kg.  It  is  intended  to  be  used  in  compound  feed  rich  in  non-starch  polysaccharides, 
containing more than 50% cereals.  
For the quantification of endo-1,3(4)- -glucanase in the feed additive, the Applicant submitted a 
single laboratory validated and further verified method, based on colour formation of released sugar 
with 3,5-dinitrosalicylic acid (DNS). The assay is based on the enzymatic hydrolysis of the barley 
betaglucan  at  pH  5.0  and  50  °C.  The  following  performance  characteristics  were  derived  from 
validation and verification studies: - a relative standard deviation for repeatability (RSDr) ranging 
from 0.8 to 3 %, - a relative standard deviation for intermediate precision (RSDip) ranging from 2.7 to 
3.9 %, and - a recovery rate (RRec) ranging from 97 to 107 %. 
For the quantification of endo-1,3(4)- -glucanase in the feed additive, premixtures and feedingstuffs 
the Applicant proposed a single laboratory validated and further verified viscosimetric method. Endo-
1,3(4)- -glucanase catalyses the hydrolysis of glycosidic bonds in the substrate (barley betaglucan) to 
yield glucose and consequently reduces the viscosity of sample solution. The decrease in viscosity of Rovabio
® Excel for poultry and pigs 
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sample solution is determined using a falling ball viscosimeter at defined conditions (pH 5.5 and 30 
°C). The following performance characteristics were derived from validation and verification studies: 
  for the feed additive: - RSDr ranging from 1.8 to 5.6 %, - RSDip ranging from 3.1 to 9.1 %, 
and - RRec ranging from 96.7 to 116.8 %; and 
  for premixtures and feedingstuffs: - RSDr ranging from 1.3 to 8.7 %, - RSDip ranging from 6.1 
to 7.6 %, - RRec ranging from 81 to 124.6 %, and limits of detection (LOD) and quantification 
(LOQ) of 576 and 738 U/kg feedingstuffs. 
For the quantification of endo-1,4- -xylanase in the feed additive, the Applicant submitted a single 
laboratory validated and further verified method, based on colour formation of released sugar with 3,5-
dinitrosalicylic acid (DNS). The assay is based on the enzymatic hydrolysis of the birchwood xylan at 
pH  4.0  and  50  °C.  The  following  performance  characteristics  were  derived  from  validation  and 
verification studies: - RSDr ranging from 0.4 to 3.5 %, - RSDip ranging from 2.7 to 2.9 %, and - RRec 
ranging from 95 to 106.8 %. 
For the quantification of endo-1,4- -xylanase in the feed additive, premixtures and feedingstuffs, the 
Applicant proposed a single laboratory validated and further verified viscosimetric method. Endo-1,4-
-xylanase catalyses the hydrolysis of xylosidic bonds in the wheat arabinoxylan substrate to yield 
xylose and consequently reduces the viscosity of sample solution. The decrease in viscosity of sample 
solution is determined using a falling ball viscosimeter at defined conditions (pH 5.5 and 30 °C). The 
following performance characteristics were derived from validation and verification studies: 
  for the feed additive: - RSDr ranging from 1.2 to 3.7 %, - RSDip ranging from 3.6 to 6.1 %, 
and - RRec ranging from 95.2 to 109.5 %; 
  for premixtures: - RSDr ranging from 2.1 to 6 %, - RSDip ranging from 3.2 to 5.8 %, and - RRec 
ranging from 79.5 to 102.1 %; and 
  for feedingstuffs: - RSDr ranging from 1.6 to 6.4 %, - RSDip ranging from 3.3 to 6.1 %, - RRec 
ranging  from  89.3  to  120  %,  and  LOD  and  LOQ  of  571  and  706  U/kg  feedingstuffs, 
respectively. 
Based on the satisfactory performance characteristics mentioned above, the EURL recommends for 
official  control  the  single  laboratory  validated  and  further  verified  methods  submitted  by  the 
Applicant, within the concentration range covered by the experimental data: 
(i)  viscosimetric methods, for the quantification of the activity of total endo-1,3(4)-β-glucanase 
and  endo-1,4- -xylanase  in  the  feed  additive,  premixtures*  and  feedingstuffs*;  (*applying 
standard addition) and 
(ii) DNS  methods,  for  the  quantification  of  total  endo-1,3(4)- -glucanase  and  endo-1,4- -
xylanase in the feed additive.  
Further  testing  or  validation  of  the  methods to  be performed  through  the consortium  of  National 
Reference Laboratories as specified by article 10 (Commission Regulation (EC) No 378/2005) is not 
considered necessary. 
 